Since their initial explosion onto the market, there is a growing pipeline demonstrating the promise of aptamer therapeutics across…

Protein-protein interactions were once considered undruggable. Our tailored aptamer selection approach is proving this isn’t so. Targets such as transcription factors, immune checkpoints in oncology, infectious disease agents, and…

One of the key benefits of using aptamers instead of antibodies is how you store and use your reagent. Over the past 60 years the stability of oligonucleotides has…

09/01/2023 Aptamer Group plc, the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces the appointment of Derek Smith as Interim Chief Commercial Officer,…

01/12/2023 Aptamer Group plc, the developer of novel Optimer® binders to enable innovation in the life sciences industry, announces a selection of new contract wins where Optimer technology is being…

28/11/2022 Baroness Susan Greenfield opened the new site and presented on the challenges in scientific discovery Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in…

From drug screening to critical assay reagents and as targeted therapeutics, aptamers are increasingly being employed across the discovery and development pipeline. Despite the large catalogues of antibodies, aptamers and…

DNA day on April 25th, celebrates major scientific achievements concerning DNA, in particular the completion of the Human Genome Project in 2003 and the discovery of DNA’s double helix…

In the age of the reproducibility crisis, working with affinity tools that offer the highest batch consistency is critical for the development of robust assays and reliable data. Aptamers,…

Gene therapy is the future for the treatment of several, often life-threatening conditions. Several gene therapy assets are currently under trial targeting cancers, sensory organs, blood disease, and rare…